YL201 (MediLink Therapeutics)

YL201 is an investigational antibody-drug conjugate (ADC) targeting B7-H3 (CD276), a transmembrane glycoprotein overexpressed in various solid tumors. Developed by MediLink Therapeutics using its proprietary TMALIN (Tumor Microenvironment Activable LINker-payload) platform, YL201 consists of a human anti-B7-H3 monoclonal antibody conjugated to a camptothecin-derived topoisomerase 1 inhibitor payload. The drug features a high drug-to-antibody ratio (DAR) of 8 and utilizes a protease-cleavable linker designed for a dual-release mechanism, allowing for payload cleavage both extracellularly within the tumor microenvironment and intracellularly within lysosomes. YL201 is currently being evaluated in Phase I/II clinical trials for advanced solid tumors, including metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC). Roche has secured exclusive global rights for the development and commercialization of YL201 outside of mainland China, Hong Kong, and Macau.

Other names

YL201 for InjectionYL-201 for InjectionYL 201 for InjectionB7-H3 ADCB-7-H3 ADCB 7-H3 ADCCD276 ADCCD-276 ADCCD 276 ADC